Table 2.

Flu/Mel/TBI 3 Gy conditioning HCT for XLP1 in Japan

Age	Symptoms	Donor Source	HLA matching	GVHD prophylaxis	aGVHD	cGVHD	Outcome	References
3 years	HLH, hypo-γ	Unrelated BM	4/6	Tacrolimus/sMTX	Grade I	None	Alive (8 years)	[5]
7 years	Hypo-γ	Unrelated BM	6/6	Tacrolimus/sMTX	None	Extensive	Alive (4 years)	[5]
15 years	HLH, ML, hypo-γ	Unrelated BM	6/6	Tacrolimus/sMTX	None	None	Alive (3 years)	[5]
20 months	Asymptomatic	Unrelated BM	8/8	Tacrolimus/sMTX	Grade I	None	Alive (2 years)	Our patient

HLH hemophagocytic lymphohistiocytosis, hypo-γ hypo gammaglobulinemia